Beyond daily dosing: Clinical experience

Bone

Volumn 38, Issue 4 SUPPL., 2006, Pages

  Cooper, C ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Adherence; Bisphosphonate; Ibandronate; Once monthly; Osteoporosis; Postmenopausal

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; PLACEBO;

ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG TOLERABILITY; DYSPEPSIA; ESOPHAGITIS; FEMUR NECK; FRAGILITY FRACTURE; GASTRITIS; GASTROENTERITIS; GASTROINTESTINAL PAIN; HUMAN; INCIDENCE; LUMBAR SPINE; NAUSEA; POST HOC ANALYSIS; POSTMENOPAUSE OSTEOPOROSIS; RISK ASSESSMENT; VOMITING;

BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS, PHASE II; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; HUMANS; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 33645098086     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2006.01.152     Document Type: Article

References (35)

1. International Osteoporosis Foundation. Osteoporosis in the European community: action plan. International Osteoporosis Foundation 2003. Available from: http://www.osteofound.org/advocacy_policy/eu_policy_project/pdf/ action_plan_03_e.pdf. Accessed 8 August 2005.
2. B.L. Riggs, and L.J. Melton III The worldwide problem of osteoporosis: insights afforded by epidemiology Bone 17 Suppl. 5 1995 505S 511S
3. International Osteoporosis Foundation. International Osteoporosis Foundation: Annual Report 2004. International Osteoporosis Foundation 2004. Available from: http://www.osteofound.org/iof/pdf/report_2004.pdf. Accessed 17 May 2005.
4. E.A. Chrischilles, C.D. Butler, C.S. Davis, and R.B. Wallace A model of lifetime osteoporosis impact Arch. Intern. Med. 151 1991 2026 2032
5. G.A. Greendale, E. Barrett-Connor, S. Ingles, and R. Haile Late physical and functional effects of osteoporotic fracture in women: the Rancho Bernardo Study J. Am. Geriatr. Soc. 43 1995 955 961
6. C. Cooper, E.J. Atkinson, S.J. Jacobsen, W.M. O'Fallon, and L.J. Melton III Population-based study of survival after osteoporotic fractures Am. J. Epidemiol. 137 1993 1001 1005
7. D.T. Gold The nonskeletal consequences of osteoporotic fractures. Psychologic and social outcomes Rheum. Dis. Clin. North Am. 27 2001 255 262
8. C.H. Chesnut III, A. Skag, C. Christiansen, R.R. RecKer, J.A. Stakkestad, and A. Hoiseth Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J. Bone Miner. Res. 19 2004 1241 1249
9. P.D. Delmas, R.R. Recker, C.H. Chesnut, A. Skag, J.A. Stakkestad, and R. Emkey Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study Osteoporos. Int. 15 2004 792 798
10. J. Reginster, H.W. Minne, O.H. Sorensen, M. Hooper, C. Roux, and M.L. Brandi Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group Osteoporos. Int. 11 2000 83 91
11. D.M. Black, S.R. Cummings, D.B. Karpf, J.A. Cauley, D.E. Thompson, and M.C. Nevitt Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group Lancet 348 1996 1535 1541
12. H.A. Pols, D. Felsenberg, D.A. Hanley, J.J. Stepan, M. Munoz-Torres, and T.J. Wilkin Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Foxamax International Trial Study Group Osteoporos. Int. 9 1999 461 468
13. S.T. Harris, N.B. Watts, and H.K. Genant Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group JAMA 282 1999 1344 1352
14. M.R. McClung, P. Geusens, P.D. Miller, H. Zippel, W.G. Benson, and C. Roux Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group N. Engl. J. Med. 344 2001 333 340
15. Alendronate prescribing information. December 2004 (www.fosamax.com).
16. Risedronate prescribing information. March 2003 (www.actonel.com).
17. R.C. Mühlbauer, F. Bauss, R. Schenk, M. Janner, E. Bosies, and K. Strein BM 21.0955, a potent new bisphosphonate to inhibit bone resorption J. Bone Miner. Res. 6 1991 1003 1011
18. F. Bauss, and R.G.G. Russell Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing Osteoporos. Int. 15 2004 423 433
19. P. Ravn, B. Clemmesen, B.J. Riis, and C. Christiansen The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of PMO: a 1-year, randomized, double-blind, placebo-controlled dose-finding study Bone 19 1996 527 533
20. R.C. Schimmer, and F. Bauss Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies Clin. Ther. 25 2003 19 34
21. B.J. Riis, J. Ise, T. Von Stein, Y. Bagger, and C. Christiansen Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis J. Bone Miner. Res. 16 2001 1871 1878
22. United States Food and Drug Administration Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis 1994 Food and Drug Administration Rockville, MD
23. M. Ettinger, R. Emkey, R.C. Schimmer, P.M. Mahoney, and J. Gilbride Efficacy of oral ibandronate in postmenopausal osteoporosis: incidence of vertebral fractures by subgroup J. Bone Miner. Res. 17 Suppl 1 2002 S206 [Abstract F341]
24. U.A. Liberman, S.R. Weiss, J. Broll, H.W. Minne, H. Quan, and N.H. Bell Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group N. Engl. J. Med. 333 1995 1437 1443
25. S.R. Cummings, D.M. Black, D.E. Thompson, W.B. Applegate, E. Barrett-Conner, and T.A. Musliner Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial JAMA 280 1998 2077 2082
26. F. Hoffmann-La Roche Ltd/GlaxoSmithKline data on file.
27. B. Ettinger, A. Pressman, and J. Schein Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis Am. J. Manag. Care 4 1998 1377 1382
28. B. Ettinger, A. Pressman, and J. Schein Alendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation J. Manag. Care Pharm. 4 1998 488 492
29. R. Kelly, and H. Taggart Incidence of gastrointestinal side effects due to alendronate is high in clinical practice BMJ 315 1997 1235
30. N. Watts, D. Freedholm, and A. Daifotis The clinical tolerability profile of alendronate Int. J. Clin. Pract., Suppl. 101 1999 51 61
31. D.C. Bauer, D. Black, K. Ensrud, D. Thompson, M. Hochberg, and M. Nevitt Upper gastrointestinal safety profile of alendronate. The Fracture Intervention Trial Arch. Intern. Med. 160 2000 517 525
32. M.F. Delaney, S. Hurwitz, J. Shaw, and M.S. LeBoff Bone density changes with once weekly risedronate in postmenopausal women J. Clin. Densitom. 6 2003 45 50
33. E.G. Lufkin, R. Argueta, M.D. Whitaker, A.L. Cameron, V.H. Wong, and K.S. Egan Pamidronate: an unrecognised problem in gastrointestinal tolerability Osteoporos. Int. 4 1994 320 322
34. C.J. Rosen, P.D. Delmas, R. Emkey, J. Gilbride, R.C. Schimmer, and B. Leishman Favorable upper gastrointestinal safety profile of ibandronate in patients with a history of gastrointestinal disorders or receiving concomitant NSAIDs Arthritis Rheum. 48 Suppl. 9 2003 S84 S85 [Abstract 102]
35. P.D. Miller, M.R. McClung, L. Macovei, J.A. Stakkestad, M. Luckey, and B. Bonvoisin Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study J. Bone Miner. Res. 20 2005 1315 1322